Benign Prostatic Hyperplasia Devices

REPORT HIGHLIGHTS

Global Benign Prostatic Hyperplasia Devices Market to Reach US$3.1 Billion by 2032

The global market for Benign Prostatic Hyperplasia Devices estimated at US$1.6 Billion in the year 2025, is expected to reach US$3.1 Billion by 2032, growing at a CAGR of 9.9% over the analysis period 2025-2032. Minimal Invasive Surgery Treatment, one of the segments analyzed in the report, is expected to record a 11.2% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Invasive Surgery Treatment segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$474.0 Million While China is Forecast to Grow at 9.3% CAGR

The Benign Prostatic Hyperplasia Devices market in the U.S. is estimated at US$474.0 Million in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$546.1 Million by the year 2032 trailing a CAGR of 9.3% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 8.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Global Benign Prostatic Hyperplasia Devices Market - Key Trends and Drivers Summarized

What Role Do Benign Prostatic Hyperplasia Devices Play in Modern Treatment?

Benign Prostatic Hyperplasia (BPH) devices are essential tools in the management of prostate enlargement, offering minimally invasive solutions that significantly reduce the symptoms and complications associated with this common condition in aging men. These devices provide alternatives to traditional surgical approaches, enabling more targeted and patient-friendly treatments. BPH devices include a range of technologies such as transurethral resection of the prostate (TURP) instruments, laser therapy systems, prostatic stents, and newer treatments like water vapor therapy and prostatic urethral lift (PUL) systems. By either removing or repositioning excess prostate tissue that blocks the urethra, these devices improve urinary flow and alleviate related symptoms like frequent urination and urinary retention. The introduction of these advanced devices has expanded the options available to men, allowing for more personalized treatment strategies that align with their specific health needs and recovery goals.

How Are Technological Innovations Enhancing BPH Device Effectiveness?

Technological innovations have significantly enhanced the effectiveness and safety of BPH devices, leading to better patient outcomes and broader treatment options. Laser therapy systems, such as holmium laser enucleation of the prostate (HoLEP), leverage precision laser technology to remove excess tissue with minimal invasiveness, reducing the risks associated with traditional surgical methods. Innovations like water vapor therapy, which utilizes steam to shrink prostate tissue, offer a non-invasive alternative with excellent long-term results. Additionally, the development of prostatic urethral lift (PUL) systems has revolutionized BPH treatment by providing a method to physically reposition the prostate tissue without cutting or removing it, thus preserving sexual function and ensuring quicker recovery. These advancements are not only improving the success rates of BPH treatments but also making them more accessible and less disruptive to patients` lives, encouraging more men to seek out these innovative solutions.

Why Is There Increasing Demand for BPH Devices Across Healthcare Systems?

The demand for BPH devices is rapidly increasing across healthcare systems due to several key trends. The growing elderly population worldwide is leading to a higher incidence of BPH, creating a greater need for effective, minimally invasive treatment options. Patients today are more informed and often prefer outpatient procedures that offer shorter recovery times and lower risks, which makes BPH devices particularly appealing. Increased awareness about BPH symptoms and the availability of advanced treatment options are prompting more men to seek medical attention earlier, thereby boosting the demand for these devices. Additionally, the shift towards value-based healthcare models, which focus on improving patient outcomes while reducing costs, is driving healthcare providers to adopt BPH devices that can deliver high-quality, efficient care. These factors are contributing to the growing utilization of BPH devices, which are becoming an integral part of modern urological care.

What Are the Key Factors Driving the Growth of the BPH Devices Market?

The growth in the BPH devices market is driven by several factors, including the rising prevalence of BPH among the aging population, which is expanding the pool of patients requiring treatment. Advances in medical technology, particularly in the development of less invasive procedures such as laser therapies and prostatic urethral lift systems, are also fueling market growth by offering safer, more effective treatment options. The increasing preference for outpatient care, which reduces hospitalization time and healthcare costs, is further boosting the adoption of these devices. Additionally, heightened awareness of BPH and its impact on quality of life is leading more men to seek early intervention, thus driving demand for innovative BPH devices. As these trends continue to evolve, the BPH devices market is expected to experience robust growth, supported by ongoing technological innovations and the rising demand for effective, patient-friendly treatment solutions.

SCOPE OF STUDY:

The report analyzes the Benign Prostatic Hyperplasia Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Procedure (TURP, Laser Therapy, Other Procedures); End-Use (Hospitals, Urology Clinics, Ambulatory Surgery Centers)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

SELECT PLAYERS -

• biolitec® Holding GmbH & Co KG.
• Boston Scientific Corporation
• Dornier MedTech GmbH
• Lumenis Be Ltd.
• Olympus Corporation
• Pnn Medical A/S
• PROCEPT BioRobotics Corporation
• Richard Wolf GmbH
• UK MEDS DIRECT Limited
• Urologix, LLC.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more